ANI Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Los beneficios de ANI Pharmaceuticals han disminuido a una tasa media anual de -0.2%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 0.1% anualmente. Los ingresos han ido creciendo a una tasa media de 22.5% al año. La rentabilidad financiera de ANI Pharmaceuticals es de 5.6%, y sus márgenes netos son de 4.3%.

Información clave

-0.2%

Tasa de crecimiento de los beneficios

-1.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	22.5%
Rentabilidad financiera	5.6%
Margen neto	4.3%
Próxima actualización de resultados	08 Nov 2024

Actualizaciones de resultados anteriores recientes

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Aug 14

Recent updates

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Feb 22

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

Oct 28

ANI Pharma launches generic Prochlorperazine maleate tablets

Aug 29

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Aug 16

ANI Pharmaceuticals Q2 2022 Earnings Preview

Aug 05

Desglose de ingresos y gastos

Cómo gana y gasta dinero ANI Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:ANIP Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 24	539	23	184	39
31 Mar 24	517	31	173	39
31 Dec 23	487	15	162	34
30 Sep 23	449	10	150	30
30 Jun 23	401	-8	129	26
31 Mar 23	359	-28	122	23
31 Dec 22	316	-50	115	22
30 Sep 22	283	-69	112	20
30 Jun 22	251	-65	99	15
31 Mar 22	226	-63	86	14
31 Dec 21	216	-43	84	11
30 Sep 21	212	-22	61	12
30 Jun 21	213	-17	66	16
31 Mar 21	213	-15	62	13
31 Dec 20	208	-23	65	16
30 Sep 20	199	-24	65	17
30 Jun 20	198	-20	57	15
31 Mar 20	203	-1	56	19
31 Dec 19	207	6	56	20
30 Sep 19	216	16	55	18
30 Jun 19	215	17	53	17
31 Mar 19	208	14	48	18
31 Dec 18	202	15	44	15
30 Sep 18	192	0	40	13
30 Jun 18	189	0	36	11
31 Mar 18	187	0	33	10
31 Dec 17	177	-1	32	9
30 Sep 17	168	7	30	7
30 Jun 17	158	5	29	5
31 Mar 17	145	4	28	4
31 Dec 16	129	4	27	3
30 Sep 16	108	8	25	3
30 Jun 16	90	10	23	3
31 Mar 16	78	12	22	3
31 Dec 15	76	15	21	3
30 Sep 15	79	33	20	3
30 Jun 15	77	35	19	3
31 Mar 15	64	30	18	3
31 Dec 14	56	29	17	3
30 Sep 14	45	11	15	3
30 Jun 14	36	5	14	2
31 Mar 14	35	1	12	2
31 Dec 13	30	-5	11	2

Ingresos de calidad: ANIP tiene una única gran ganancia de $8.9M que afecta a sus resultados financieros de los últimos 12 meses de 30th June, 2024.

Margen de beneficios creciente: ANIP pasó a ser rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ANIP ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de -0.2% al año.

Acelerando crecimiento: ANIP ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.

Beneficios vs. Industria: ANIP ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (36.7%).

ANI Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind